GlassScriptPhysician profile
Arthur R Menezes
NPI 1457670440
$16,508.43
in general payments reported to CMS, 2019-2025
39 companies · $4,290 in 2025
The $4,290 reported for 2025 was more than what 81% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,475 · 2020: $1,442 · 2021: $1,305 · 2022: $2,307 · 2023: $1,467 · 2024: $4,222 · 2025: $4,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,459 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,100 · Consulting Fee: $1,400 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,459.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,100.00 |
| Consulting Fee | $1,400.00 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $5,152.21 | 2022-2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $1,792.94 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,544.50 | 2019-2024 | Lifevest |
| Abbott Laboratories | $992.02 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $850.34 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| Janssen Pharmaceuticals, INC | $707.63 | 2019-2024 | Xarelto |
| Pfizer INC. | $541.36 | 2019-2025 | |
| Amgen INC. | $450.15 | 2019-2025 | Repatha, Repatha |
| Cvrx, INC. | $441.58 | 2020-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $403.90 | 2019-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $386.82 | 2019-2025 | General - Ep, Emblem Mri S-Icd |
| Merck Sharp & Dohme LLC | $362.16 | 2021-2025 | Verquvo, Capvaxive |
| Abiomed | $303.16 | 2019-2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.46 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $235.81 | 2019-2023 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $217.22 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $207.89 | 2019-2025 | Lokelma, Farxiga |
| Impulse Dynamics (USA) INC. | $194.71 | 2022-2023 | Optimizer |
| Biotronik INC. | $194.45 | 2021-2025 | Amvia Edge |
| Cardiovascular Systems INC. | $193.63 | 2019-2020 | |
| Chiesi USA, INC. | $155.45 | 2019-2023 | Kengreal, Cleviprex |
| Medtronic, INC. | $135.70 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $124.15 | 2024 | |
| Shockwave Medical, INC | $65.33 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Alnylam Pharmaceuticals INC. | $64.52 | 2022-2025 | Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $64.08 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $61.76 | 2025 | Pascal |
| Kiniksa Pharmaceuticals, LTD. | $56.10 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $54.63 | 2019 | |
| Novo Nordisk INC | $49.54 | 2025 | Wegovy |
| Amarin Pharma, INC. | $41.61 | 2020 | |
| Esperion Therapeutics, INC. | $38.81 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $28.76 | 2019 | |
| Penumbra, INC. | $25.18 | 2024 | Indigo System |
| Tactile Systems Technology INC | $23.92 | 2019 | |
| Baxter Healthcare | $19.51 | 2024 | Perclot |
| Lundbeck LLC | $15.41 | 2019 | |
| Janssen Biotech, INC. | $14.01 | 2024 | Opsumit |
| Astellas Pharma US INC | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Menezes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.